retatrutide eli lilly phase 2 results Shows Promising in Obesity and Diabetes Treatment | Mina Gereis posted on the topic Lilly's triple agonist, retatrutide, delivered

The summary of approval dates for these GLP-1RAs is listed in Supplementary Table 1

Thus, GLPs and DPP-IV inhibitors have recently gained attention in IBD research (Lund et al

Instead of prescribing an antidepressant that might cause weight gain (making one problem better while worsening the other), we can consider a low-dose GLP-1 that might help both while the patient engages in therapy and lifestyle changes

Its triple receptor mechanism offers researchers an opportunity to study multiple biological pathways within a single experimental model

doi: 10.1007/s12020-019-02055-z 93 PintoLCFalcettaMRRadosDVLeitaoCBGrossJL